ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. [Yahoo! Finance]
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: Yahoo! Finance
Discontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentially preserve kidney function in patients with type 2 diabetes and advanced CKD. ProKidney recently completed a comprehensive internal and external review, including engaging with ex-FDA officials and seasoned regulatory experts, to determine the optimal path to bring rilparencel to patients in the U.S. with type 2 diabetes and advanced CKD – a market where there is high unmet clinical and economic need. An important conclusion of this review is th
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- ProKidney Corp. (NASDAQ: PROK) is now covered by analysts at Guggenheim. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- ProKidney drops Phase III CKD study to focus on US market and save up to $175m [Yahoo! Finance]Yahoo! Finance
- ProKidney Corp. (NASDAQ: PROK) had its price target lowered by analysts at Bank of America Co. from $4.00 to $3.00. They now have a "neutral" rating on the stock.MarketBeat
- ProKidney revises Phase 3 program for lead asset [Seeking Alpha]Seeking Alpha
- ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.GlobeNewswire
PROK
Earnings
- 8/9/24 - Beat
PROK
Sec Filings
- 9/20/24 - Form 4
- 9/19/24 - Form 144
- 9/16/24 - Form 4
- PROK's page on the SEC website